FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

UPPALURI SUBBARAO V 		2. Issuer Name and Ticker or Trading Symbol

Winston Pharmaceuticals, Inc. [ WPHM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O WINSTON PHARMACEUTICALS, INC., 100 N. FAIRWAY DRIVE, SUITE 134 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/24/2009
(Street)

VERNON HILLS, IL 60061
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

9/28/2009 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock   (1) $0.00   9/24/2009     C         127   (1) (2) (3)     (1) (2)   (1) (2) Common Stock   127000   (1) (2) (3) $0   0   D    

Explanation of Responses:
( 1)  This Form 4 is being filed to amend a line of transaction information appearing on a previously-filed Form 4, which was previously filed on September 28, 2009, in which (i) column 5 of Table II inadvertently and erroneously indicated that Mr. Uppaluri had disposed of 229 shares of Series A Convertible Preferred Stock and (ii) column 7 of Table II inadvertently and erroneously indicated 229,000 shares of Common Stock (as defined below) underlying such Series A Convertible Preferred Stock. This Form 4 amends such line of transaction information as follows: (i) column 5 of Table II has been amended to indicate that Mr. Uppaluri disposed of 127 shares of Series A Convertible Preferred Stock; and (ii) column 7 of Table II has been amended to indicate 127,000 shares of Common Stock (as defined below) underlying such Series A Convertible Preferred Stock.
( 2)  Effective September 24, 2009, each outstanding share of Winston Pharmaceuticals, Inc. (the "Company") Series A Convertible Preferred Stock, par value $0.001 per share ("Series A Preferred Stock"), automatically converted into 1,000 shares of the Company's common stock, par value $0.001 per share ("Common Stock").
( 3)  Reported amounts reflect share ownership subsequent to the effectuation by the Company on December 15, 2008 (the "Reverse Split Date") of a 1-for-8 reverse stock split whereby each eight shares of the Company's common stock and preferred stock either issued and outstanding or held as treasury shares immediately prior to the Reverse Split Date were automatically reduced and continued as one share of the Company's common stock or preferred stock, as applicable. All of the Company's outstanding securities were adjusted accordingly to reflect such reverse split.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
UPPALURI SUBBARAO V
C/O WINSTON PHARMACEUTICALS, INC.
100 N. FAIRWAY DRIVE, SUITE 134
VERNON HILLS, IL 60061 		X



Signatures
/s/ Uppaluri, Subbarao V. 3/10/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Winston Pharmaceuticals (CE) (USOTC:WPHM)
過去 株価チャート
から 10 2024 まで 11 2024 Winston Pharmaceuticals (CE)のチャートをもっと見るにはこちらをクリック
Winston Pharmaceuticals (CE) (USOTC:WPHM)
過去 株価チャート
から 11 2023 まで 11 2024 Winston Pharmaceuticals (CE)のチャートをもっと見るにはこちらをクリック